Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

Renal Insufficiency Clinical Trial

— ATG_HVH  

Official title:

Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01453218
• Other study ID #: ATG-IRA-HVH.10
• Secondary ID: 2011-000691-34
• Status: Completed
• Phase: Phase 3
• Start date: October 2011
• Est. completion date: February 2020

Study information

• Verified date: February 2020
• Source: Hospital Vall d'Hebron
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.

Physiopathologically pretransplant renal dysfunction is dependent on multifactorial causes, including hypoperfusion-derived functional renal insufficiency, hepatorenal syndrome or interstitial parenchymatous insufficiency. On top, intra- or post-transplant events, including hypoperfusion or calcineurin inhibitors nephrotoxicity may aggravate this situation.

At present MELD criteria favours allocation of organs to patients suffering from renal insufficiency, so at least 30% of the investigators liver transplant patients suffer from some degree of renal impairment pretransplant.

After liver transplant impaired renal function tends to recover partially or completely, unless advanced parenchymatous lesions are significantly involved as a major cause of renal dysfunction.

In this context, calcineurin inhibitors avoiding or sparing protocols may help in the recovery from renal insufficiency, improving long-term prognosis. The use of anti-CD25 antibodies is a good option, but provides a limited antirejection prophylaxis, limiting the use of these antibodies to a reduced cohort of liver transplant patients.

Polyclonal antibodies might provide an advantage in management of liver transplant patients with renal insufficiency, without increasing acute rejection episodes of the allograft efficacy and security evaluation of low nephrotoxicity immunosuppression, based on the use of ATeGe, in liver transplant candidates with pre-transplant renal dysfunction.

The aim of this study is to evaluate the efficacy and security use of immunosuppression based on ATeGe in liver transplant recipients with pre-transplant renal dysfunction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 2020
• Est. primary completion date: February 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with moderate pre-transplant renal dysfunction as defined serum creatinine levels higher than 1.5 mg/dl or eGFR (MDRD-4) <60ml/min.

• First liver transplant, including splits liver transplant.

• Patients aged 18-70 years

• Without a prior contraindication for protocol biopsy of allograft.

Exclusion Criteria:

• Multiorgan transplantation and/or liver transplant from DCD and/or with ABO incompatibility.

• Uncontrolled concomitant infections (including HIV seropositivity) and/or diarrhoea, vomiting or active gastric ulcer.

• Fulminant hepatic insufficiency as first indication for liver transplant

• Hemodynamic instability prior to liver transplant.

• Recipient presenting present or previous neoplasia, except for non-metastatic basal or squamous cutaneous carcinoma or localized hepatocarcinoma with diameter <5 cm or < 3 known lesions with diameter <3 cm.

• Intolerance to study medication.

• Patients having received vaccination with attenuated living vaccines within the previous 4 weeks.

• Severe leukopenia (< 1.2 X 10E9/L) and/or thrombocytopenia (< 50x10E9/L) and/or lymphocyte counts (CD2+/CD3+) less than 10 cells/µl.

• Significant comorbidity.

• Breastfeeding or female patients at fertile age without negative pregnancy test and accepting the use of reliable fertility control method.

Related Conditions & MeSH terms

• Renal Insufficiency

Intervention

Drug:
• ATeGe-Fresenius
Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels

Locations

Country	Name	City	State
Spain	Department of HPB Surgery and Transplants, Hospital Vall d´Hebron	Barcelona

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Vall d'Hebron	Hospital Universitari Vall d'Hebron Research Institute

Country where clinical trial is conducted

Spain, 

References & Publications (7)

Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 2008 Jan;14(1):66-72. — View Citation

Benítez CE, Puig-Pey I, López M, Martínez-Llordella M, Lozano JJ, Bohne F, Londoño MC, García-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sánchez-Fueyo A. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant. 2010 Oct;10(10):2296-304. doi: 10.1111/j.1600-6143.2010.03164.x. — View Citation

Kim MJ, Tsinalis D, Franz S, Binet I, Gürke L, Mihatsch MJ, Steiger J, Thiel G, Dickenmann M. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant. 2008;13(4):21-7. — View Citation

Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, Mühlbacher F, Berlakovich GA. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 2007 Jul;13(7):1039-44. — View Citation

Soliman T, Hetz H, Burghuber C, Györi G, Silberhumer G, Steininger R, Mühlbacher F, Berlakovich GA. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 2007 May;20(5):447-52. Epub 2007 Mar 2. — View Citation

Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 2004 Mar;10(3):404-7. — View Citation

Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int. 2011 Jul;24(7):640-50. doi: 10.1111/j.1432-2277.2011.01250.x. Epub 2011 Mar 23. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Renal function improvement after liver transplant	Creatinine (mg/dL) and MDRD Glomerular Filtrate Rate (ml/min/1.73m2) will be measured following the time frame described above	Measurement will be performed at 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th and 28th day post-transplant, and 2nd, 3rd, 6th and 12th month post-transplant
Secondary	Incidence of biopsy proven acute cellular rejection.	If liver dysfunction is detected, percutaneous liver biopsy will be performed and histological severity will be assed following BANF criteria	Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
Secondary	Patient and graft survival rates after 12 months, causes of death and retransplant		Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
Secondary	Relationship between ATeGe doses, immunological variables (lymphocyte counts) and clinical adverse events (acute rejection,infections, HCV recurrence and de novo tumor)		Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant
Secondary	Incidence and severity of HCV infection recurrence, based on clinical and histological criteria.		Once liver dysfunction is detected and one year post-transplant by protocol.
Secondary	Evaluation of metabolic complications (diabetes mellitus, arterial hypertension and dyslipidemia)		Evaluation at 1st , 3rd, 6th, 9th and 12th month post-transplant